Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Rigel to cut R&D

by Rick Mullin
September 26, 2016 | A version of this story appeared in Volume 94, Issue 38

Rigel Pharmaceuticals is restructuring after receiving positive Phase III clinical results for fostamatinib, its oral SKY inhibitor for chronic immune thrombocytopenia, an autoimmune disease. The company says it will reduce its staff by 38%—eliminating 46 positions, mostly in research—as it builds a commercial organization to support the anticipated launch of the drug. The move is expected to save up to $20 million annually.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.